Department of Urology, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Rev Endocr Metab Disord. 2022 Dec;23(6):1221-1231. doi: 10.1007/s11154-022-09730-z. Epub 2022 Jun 24.
Due to late onset hypogonadism (LOH), there is an increased usage of testosterone replacement therapy (TRT) in the aging male population. Since prostate is a target organ for androgens and anti-androgenic strategies are used to treat and palliate benign prostate hyperplasia (BPH) and prostate cancer (PC), the prevalence of both increases with age, the possible influence of TRT on prostate health becomes highly relevant. The present review summarizes existing data on the associations between endogenous hormone concentrations and prostate growth and concludes that circulating concentrations of androgens do not appear to be associated with the risks of development of BPH or initiation or progression of PC. The explanation for these findings relates to an apparent insensitivity of prostatic tissue to changes of testosterone concentrations within the physiological range.
由于迟发性性腺功能减退症（LOH）的出现，老年男性人群中睾酮替代疗法（TRT）的使用有所增加。由于前列腺是雄激素的靶器官，抗雄激素策略被用于治疗和缓解良性前列腺增生（BPH）和前列腺癌（PC），随着年龄的增长，这两种疾病的患病率都在增加，因此 TRT 对前列腺健康的可能影响变得非常重要。本综述总结了现有关于内源性激素浓度与前列腺生长之间关联的数据，并得出结论，循环雄激素浓度似乎与 BPH 的发展风险或 PC 的起始或进展无关。这些发现的解释与前列腺组织对生理范围内睾酮浓度变化的明显不敏感性有关。
